Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 5/20 | 0.63 |
| ▸ | LRRK2 | Q5S007 | 14/20 | 0.58 |
| ▸ | TTK | P33981 | 1/20 | 0.52 |
| ▸ | ULK1 | O75385 | 1/20 | 0.52 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27087778 | 1.00 | PTK2 (0.63) | PTK2LRRK2TTKULK1ULK2 | |
| SCHEMBL27403030 | 0.93 | PTK2 (0.61) | PTK2LRRK2TTK | |
| SCHEMBL27403034 | 0.92 | PTK2 (0.69) | PTK2LRRK2 | |
| SCHEMBL27403041 | 0.92 | PTK2 (0.57) | PTK2LRRK2TTKULK1ULK2 | |
| SCHEMBL30940257 | 0.91 | LRRK2 (0.64) | PTK2LRRK2TTKULK1ULK2 | |
| SCHEMBL27403039 | 0.91 | LRRK2 (0.64) | PTK2LRRK2TTKULK1ULK2 | |
| SCHEMBL29989274 | 0.90 | PTK2 (0.66) | PTK2LRRK2 | |
| SCHEMBL27087805 | 0.90 | PTK2 (0.66) | PTK2LRRK2 | |
| SCHEMBL29989835 | 0.90 | LRRK2 (0.72) | LRRK2TTK | |
| SCHEMBL27403032 | 0.90 | LRRK2 (0.72) | LRRK2TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | LIFEARC (GB) | 2024-06-27 | — | — | US | disclosed |
| EP-4320121-A2 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES AS ULK1/2 INHIBITORS AND THEIR USE THEREOF | LifeArc (GB) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022214869-A2 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | LIFEARC (GB) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | PTK2 1096/4885LRRK2 827/4885TTK 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.